Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says
Eli Lilly & Co. argued Thursday that the first federal bellwether trial over the bladder cancer risks of diabetes drug Actos should exclude evidence about its fines for marketing the antipsychotic...To view the full article, register now.
Already a subscriber? Click here to view full article